Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

End Stage Renal Disease

Part of Chronic Kidney Disease

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for End Stage Renal Disease

136 trials tracked for End Stage Renal Disease: 33 in phase 3 or 4 and 14 with published results. The most-cited published study has 296 citations.

136Trials tracked

33Phase 3 & 4

0Recruiting

14With published results

Phase distribution

Phase 4 17 Phase 3 16 Phase 2 36 Phase 1 12 Other / NA 55

Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 296 cited
Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 278 cited
Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 226 cited
Phase 3 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND} Completed · 115 cited
Phase 3 Journeys to Wellness: A Transplant Candidate Study Completed · 67 cited
Phase 4 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors Completed · 49 cited

Show 44 more trials

Phase 4 Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Completed · 46 cited
Phase 4 Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease Completed · 37 cited
Phase 3 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae Completed · 29 cited
Phase 3 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis Completed · 22 cited
Phase 3 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Completed · 19 cited
Phase 4 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Completed · 18 cited
Phase 3 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis Completed · 13 cited
Phase 4 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed · 3 cited
Phase 4 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Completed
Phase 4 Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients Completed
Phase 4 Triferic AVNU Infusion Via Freedom Pump During Hemodialysis Completed
Phase 4 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis Completed
Phase 4 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation Completed
Phase 4 Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients Completed
Phase 4 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation Completed
Phase 4 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed
Phase 4 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed
Phase 4 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed
Phase 3 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed
Phase 3 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans Completed
Phase 3 Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Completed
Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
Phase 3 A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis Completed
Phase 3 Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis Completed
Phase 3 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed
Phase 3 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed
Phase 3 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access Completed
Phase 2 Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis Completed
Phase 2 C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Completed
Phase 2 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Completed
Phase 2 Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis Completed
Phase 2 Bone Mass and Strength After Kidney Transplantation Completed
Phase 2 Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients Completed
Phase 2 Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Completed
Phase 2 Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation Completed
Phase 2 Safety and Dose Finding Study of Xigris in Hemodialysis Patients Completed
Phase 2 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis Completed
Phase 2 Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis Completed
Phase 2 The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Completed
Phase 2 Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation Completed
Phase 2 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease Completed
Phase 2 Renal Allograft Tolerance Through Mixed Chimerism Completed
Phase 2 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Completed
Phase 2 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome Completed

Showing the 50 most-cited and recently-updated of 136 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

End Stage Renal Disease: what the trials found

Cinacalcet was shown to significantly improve mineral metabolism in patients with chronic kidney disease, specifically resulting in a higher number of participants achieving mean PTH ≤ 300 pg/mL ²⁰, and a significant increase in the number of patients achieving both Ca x P < 55 mg^2/dL^2 and iPTH ≤ 300 pg/mL ²⁰. Additionally, cinacalcet was associated with an absolute reduction in PTH levels ²¹.

Patiromer significantly reduced the total number of episodes of serum potassium ≩ 5.5 mEq/L compared to the control group ⁸.

In patients with end-stage renal disease on dialysis, the 13-valent conjugate pneumococcal vaccine resulted in various changes from baseline in antibody concentrations ⁹.

Recent results — preliminary, needs further review

• The Ellipsys Vascular Access System demonstrated a cumulative patency of 99.1% over 12 months with a low early occlusion rate of 1.5% ¹.
• Educational interventions regarding kidney donation and transplant significantly improved knowledge regarding living donor kidneys ².
‣ Patient activation programs were evaluated for their impact on dialysis adherence, showing mean weekly minutes missed ranging from approximately 4.89 to 5.28 ⁴.

For the clinician treating this condition

Cinacalcet is effective for managing secondary hyperparathyroidism and mineral metabolism in renal patients [20, 21].
Patiromer is an effective intervention for controlling hyperkalemia by reducing the frequency of high potassium episodes ⁸.
The Ellipsys Vascular Access System shows high patency rates for vascular access in dialysis patients ¹.

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

1 2 Next ›

Questions about End Stage Renal Disease

Does symptom distress negatively affect quality of life in hemodialysis patients?

Yes, symptom distress — including post-dialysis fatigue, itching, anxiety, and depression — significantly reduces quality of life in hemodialysis patients.

Full answer →

How does nutrition education improve quality of life for adults with End Stage Renal Disease on dialysis?

Nutrition education significantly improves quality of life and dietary knowledge for adults on dialysis, according to a meta-analysis of 44 studies.

Full answer →

All End Stage Renal Disease Articles